Psilocybin for Anxiety: What the Research Shows
Lasting relief in cancer-related anxiety, a positive generalized anxiety trial and early Colorado data: what the research shows and where it's still thin.
In this article
Anxiety is where modern psilocybin research began. Some of the first clinical trials of this era, at UCLA, Johns Hopkins and NYU, enrolled people who were anxious and depressed after a life-threatening cancer diagnosis. One supported session eased that anxiety, and for most people the relief was still there six months later.
What that means for someone with generalized anxiety, panic or social anxiety is a separate question, and the answer has moved in the last two years. Below is what each line of research found, what is encouraging and where the evidence is still thin.
The short answer
Psilocybin with psychological support has relieved anxiety in most of the controlled trials that measured it. The effect shows up quickly, and in the longest follow-ups it held for months to years.
The strongest evidence is in people facing serious illness. Two randomized trials with 80 people found large drops in anxiety and depression after a single high-dose session. About 60% to 80% still had a clinically significant benefit six months later.
For generalized anxiety the evidence is newer and points the same way. In the first placebo-controlled trial, 73 people with generalized anxiety disorder improved far more with two psilocybin sessions than with therapy and a placebo. In 2026 two Phase 3 trials of LSD, a different psychedelic, also found a benefit in generalized anxiety. Since they act on the same receptor, we can infer some cross-benefit.
For panic disorder, social anxiety and phobias there are no controlled psilocybin trials yet. Cognitive behavioral therapy and exposure are still the treatments with the most evidence.
It is not FDA-approved for anxiety, and it is legal and regulated in Colorado. The application the FDA is reviewing as of November 2026 covers treatment-resistant depression only. Colorado’s licensed program is open now to adults 21 and older.
Where it started: anxiety in serious illness
UCLA, 2011. A pilot study in Archives of General Psychiatry gave 12 adults with advanced cancer and anxiety a moderate dose of psilocybin (0.2 mg/kg) in one session and a placebo in another. There were no clinically significant adverse events, and trait anxiety was lower one and three months later. It was a safety study, and it reopened a line of research that had been closed since the early 1970s.
Johns Hopkins, 2016. The Hopkins trial enrolled 51 people with life-threatening cancer and symptoms of anxiety or depression. Each had two sessions five weeks apart: one with a high dose (22 or 30 mg per 70 kg of body weight) and one with a very low dose (1 or 3 mg per 70 kg) that served as the comparison. Participants and staff weren’t told which was which. The high dose produced large decreases in anxiety and depressed mood on both clinician ratings and self-ratings. Quality of life, sense of meaning and optimism rose, and fear of death fell. At six months about 80% of participants still showed a clinically significant improvement.
NYU, 2016. The companion trial at NYU randomly assigned 29 people with cancer-related anxiety and depression to a single dose of psilocybin (0.3 mg/kg) or niacin, a vitamin used as an active placebo. Both groups received psychotherapy, and the groups switched after seven weeks. Before the switch, the psilocybin group improved immediately and substantially on anxiety and depression. At six and a half months roughly 60% to 80% still had clinically significant reductions.
Four and a half years later. Researchers went back to the NYU participants an average of 3.2 and 4.5 years after their session. Of the 16 who were still alive, 15 took part. Their reductions in anxiety, depression, hopelessness and death anxiety had held, and 60% to 80% still met the threshold for a clinically significant response. Between 71% and 100% credited the session with positive life changes and rated it among the most meaningful experiences of their lives. By then everyone in the trial had received psilocybin, so there was no comparison group, and the authors say so.
A 2021 meta-analysis pooled five trials and concluded that psilocybin with therapy eased anxiety in people with life-threatening illness without serious adverse events. It also called for larger trials.
In both 2016 trials, how strongly a person rated the session as a mystical-type experience helped explain how much they improved. We cover that finding in mystical experience and therapeutic outcomes.
A larger test is under way in Colorado. The University of Colorado Anschutz Medical Campus and NYU are running a trial funded by the National Cancer Institute for people with advanced cancer. It compares a single 25 mg dose with niacin, and both groups receive 6 hours of preparation and 8 hours of integration therapy. The trial registry listed it as still enrolling in October 2026.
Generalized anxiety: the first direct trial
Until 2024 no controlled trial had tested psilocybin for generalized anxiety disorder itself.
The first was run by Incannex Healthcare with the Clinical Psychedelic Lab at Monash University in Melbourne. It enrolled 73 adults with moderate to severe generalized anxiety disorder. Everyone went through the same seven-week program of psychotherapy with two dosing sessions. One group received 25 mg of psilocybin at each and the other received a placebo.
Six weeks after the second session, scores on the Hamilton Anxiety Rating Scale (HAM-A), a 56-point clinician rating, had fallen by 12.8 points in the psilocybin group and 3.6 points in the placebo group. In the psilocybin group 44% had improved by at least half and 27% were in remission. Depression, disability and wellbeing scores improved too. No serious adverse events were reported, and one person left the trial.
Those are strong numbers. They also come from the company’s own reports, in February 2024 and August 2025. As of this writing the full results haven’t appeared in a peer-reviewed journal, and one trial of 73 people needs repeating. A larger trial is planned.
Anxiety in the depression trials
Most psilocybin trials for depression also measured anxiety, since the two so often come together. A 2024 systematic review of randomized trials in major depression found five that tracked anxiety. In four of them the psilocybin group’s anxiety improved significantly more than the comparison group’s.
If your anxiety and depression run together, the depression research applies to you as well. We go through it trial by trial in psilocybin for depression: what the research shows.
What the LSD trials add
LSD and psilocybin are both classic psychedelics, and both act mainly on the serotonin 2A receptor. The largest anxiety trials of any psychedelic have used LSD.
In 2026 Definium Therapeutics, formerly MindMed, reported two Phase 3 trials of a pharmaceutical LSD tablet for generalized anxiety disorder. In the first, 214 adults in the US received a single 100 microgram dose or a placebo. Twelve weeks later HAM-A scores had dropped 11.6 points with LSD and 6.2 points with placebo, and 43% of the LSD group had improved by at least half compared with 16%. The second, with 245 adults in the US and Europe, found a similar gap: 9.8 points compared with 4.7.
These are summary results announced by the company, and the full papers haven’t been published. The company has said it plans to ask the FDA for approval in the first half of 2027.
A result for one drug doesn’t transfer automatically to another. Still, two large blinded trials now suggest that a single dose of a classic psychedelic can ease generalized anxiety for at least three months, and psilocybin’s own trial points the same way. LSD isn’t part of Colorado’s program. Psilocybin is the classic psychedelic you can use legally here today.
How long it lasts
In the cancer trials the benefit held at six months, and in the small NYU follow-up it held at four and a half years. In the generalized anxiety trial the last measurement came six weeks after the second session. The LSD trials followed people for 12 weeks after a single dose.
No trial has yet followed people with an anxiety disorder for a full year after psilocybin. That’s one of the main things the next round of studies needs to answer.
Anxiety during the session
A treatment for anxiety that can cause anxiety deserves a plain explanation.
In the Hopkins trial, 26% of high-dose sessions included an episode of anxiety, compared with 15% of very-low-dose sessions. At NYU, 17% of participants had transient anxiety. These episodes passed during the session, and the NYU team reported no serious adverse events from psilocybin.
Psilocybin also raises heart rate and blood pressure for a few hours. In the Hopkins trial about a third of high-dose sessions included a systolic reading above 160. If a racing heart is one of the things you fear, it helps to expect that ahead of time.
Moments of fear are an expected part of a session, and they are what preparation, the setting and a facilitator in the room are for. People are taught beforehand to turn toward what comes up and to ask for support when they need it. See how to prepare for a psilocybin journey, what happens in a session and set and setting.
Why these studies are hard to read
Blinding barely works. People almost always know whether they received a full dose. Expectation can lift results in the psilocybin group and disappointment can hold them down in the comparison group.
The trials are small. Hopkins enrolled 51 people, NYU 29 and the generalized anxiety trial 73. Small trials tend to overstate effects. In the depression research, the larger trials that followed found smaller ones.
Fear after a cancer diagnosis is not the same as an anxiety disorder. Fear of dying has an object. Generalized anxiety, panic and social anxiety are kept going by worry and avoidance, and they may respond differently. The cancer trials are encouraging for anxiety disorders, and they don’t settle the question.
Some results come from companies. The generalized anxiety trial and both LSD trials were announced by the companies developing the drugs, and the full data haven’t been through peer review.
Participants are carefully screened. These trials excluded people with a history of psychosis or mania and people with unstable medical conditions.
The support was part of the treatment. In the psilocybin trials the session came with hours of preparation and follow-up therapy, so nobody knows how much of the benefit belongs to the drug alone.
The same cautions apply to the research on psilocybin for OCD and psilocybin for alcohol and addiction.
Where psilocybin fits
Cognitive behavioral therapy and exposure have decades of controlled trials behind them across the anxiety disorders, and most people who complete a full course improve. If you haven’t had one, that is usually where we’d start. Many people who say therapy didn’t help had supportive therapy without exposure, which is a different treatment. See anxiety treatment at FRTC, what happens in CBT for anxiety and how CBT, DBT and exposure differ.
For panic disorder, social anxiety and phobias, exposure-based treatment is the only option with trial evidence so far. We describe ours on the panic disorder and social anxiety pages. When anxiety comes with intense emotion that makes exposure hard to start, DBT for anxiety can come first.
Psilocybin is a reasonable thing to ask about when:
- anxiety has stayed with you through a full course of CBT or exposure, or through medication
- your anxiety is tied to a serious illness, a loss or questions about meaning and mortality, the kind of distress the cancer trials studied
- anxiety and depression run together
- you’d prefer one or two supported sessions to adding another daily medication
It doesn’t have to be one or the other. In every psilocybin trial the session was added to psychological support, and many people keep their therapy going around it.
What this means in Colorado
Adults 21 and older can work with a licensed facilitator in Colorado now, with no wait for the FDA. A facilitated session includes screening, preparation, the session itself and integration.
It is a different thing from the treatment studied in the trials. Those were medical research, run by teams that included physicians, with standardized measurement at every step. Facilitators aren’t prescribers, and a session on its own is not a treatment plan for an anxiety disorder.
There is early data on how regulated programs are going. A 2026 preprint analyzed records from 2,363 people who received psilocybin at licensed service centers in Oregon and Colorado. Two-thirds reported a mental health concern going in. Two weeks after the session, scores on a standard anxiety questionnaire had fallen by 51% and depression scores by 49%. The authors counted 94 mild adverse events and five more serious ones that weren’t clearly related to the session. They also saw signs of a possible increase in suicidal thinking in some people and called for closer monitoring. A preprint hasn’t been peer reviewed. This one had no comparison group, relied on self-report, lost many people to follow-up and stopped at two weeks. It is encouraging and it is early.
What that means in practice:
You don’t have to stop an antidepressant. Many people with anxiety take an SSRI or SNRI. We don’t ask anyone to taper one for a session. Any medication change is a decision for you and your prescriber, and facilitators can’t direct one. We cover both sides of the question in psilocybin and SSRIs. Lithium and MAOIs rule a session out.
Tell us about benzodiazepines. They blunt the experience. A dose taken only as needed is usually skipped that day. Daily use is different: stopping abruptly is dangerous, so it calls for a plan with your prescriber well before a date is set. See psilocybin contraindications.
Screening asks about your whole history. A history of mania or psychosis rules a session out, and so do active suicidal thoughts with a plan. Screening also covers heart health, because blood pressure rises during a session. See how screening works.
Preparation carries more weight when anxiety is the concern. Knowing what the hours will feel like, and having practiced how to meet a hard moment, changes how those moments go.
Plan for integration. If you have a therapist or a prescriber, keep them informed, and treat integration as part of the work.
The bottom line
Psilocybin’s record for anxiety is strongest where the research started, in people facing a life-threatening illness. In that group a single supported session brought relief that lasted months and, in one small follow-up, years.
For generalized anxiety the first controlled trial was clearly positive, and two large trials of a closely related psychedelic found the same thing in 2026. For panic, social anxiety and phobias the trials haven’t been done.
It isn’t a cure and it doesn’t replace CBT or exposure. The anxiety disorder research is younger than the depression research, and much of it is still waiting for peer review.
In Colorado the option is open now, with screening, preparation and integration built in. If anxiety has outlasted what you’ve tried, or it is tied to illness, loss or meaning, it’s worth a conversation.
Considering natural medicine for anxiety? Get in touch or book a free 15-minute consultation. We’ll talk through your history, including whether CBT or exposure should come first. You may also want to read is psilocybin therapy right for you, how psilocybin works or learn about our natural medicine services.
This post is educational and is not medical advice. Psilocybin sessions under Colorado’s Natural Medicine Health Act are not a substitute for treatment of an anxiety disorder. Don’t stop or change a psychiatric medication without talking to your prescriber.
At FRTC in Denver
Psilocybin-assisted therapy at FRTC
State-licensed facilitators, under Colorado’s Natural Medicine Health Act. Each journey has preparation before and integration after.
Ask about natural medicine services
Tell us how to reach you and we’ll get back to you — usually within one business day.
Booking for Natural Medicine Services
The calendar is thin right now — send a message and we’ll reply within one business day.